Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00354250
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
NIH
Sponsor class
Conditions
Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer
Interventions
DRUG:
ispinesib
Sponsor
National Cancer Institute (NCI)